SK11842000A3 - Prostriedok obsahujúci vírus, spôsob jeho koncentrácie a purifikácie - Google Patents

Prostriedok obsahujúci vírus, spôsob jeho koncentrácie a purifikácie Download PDF

Info

Publication number: SK11842000A3
Authority: SK; Slovakia
Prior art keywords: virus; composition; concentration; preparation; viral
Prior art date: 1998-02-17

Application number

SK1184-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Andreas Frei

Henry K. H. Kwan

Varda E. Sandweiss

Gary J Vellekamp

Pui-Ho Yuen

Bondoc Laureano L., Jr.

Frederick William Porter Iv

John Chu-Tay Tang

Peter Ihnat

Original Assignee

Schering Corporation

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-17

Filing date

1999-02-12

Publication date

2001-05-10

1999-02-12 Application filed by Schering Corporation filed Critical Schering Corporation

2001-05-10 Publication of SK11842000A3 publication Critical patent/SK11842000A3/sk

Links

241000700605 Viruses Species 0.000 title claims abstract description 113
238000002360 preparation method Methods 0.000 title claims abstract description 83
238000000034 method Methods 0.000 title claims abstract description 69
239000000203 mixture Substances 0.000 title claims description 81
229930195733 hydrocarbon Natural products 0.000 claims abstract description 43
150000002430 hydrocarbons Chemical class 0.000 claims abstract description 43
238000001914 filtration Methods 0.000 claims abstract description 25
239000004215 Carbon black (E152) Substances 0.000 claims abstract description 14
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 93
230000003612 virological effect Effects 0.000 claims description 58
239000002245 particle Substances 0.000 claims description 45
229930006000 Sucrose Natural products 0.000 claims description 18
239000002904 solvent Substances 0.000 claims description 18
239000005720 sucrose Substances 0.000 claims description 18
150000003839 salts Chemical class 0.000 claims description 17
241000701161 unidentified adenovirus Species 0.000 claims description 15
238000005571 anion exchange chromatography Methods 0.000 claims description 13
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 13
238000003860 storage Methods 0.000 claims description 11
238000001542 size-exclusion chromatography Methods 0.000 claims description 10
229960000281 trometamol Drugs 0.000 claims description 10
238000001415 gene therapy Methods 0.000 claims description 9
230000008569 process Effects 0.000 claims description 9
VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
108700019146 Transgenes Proteins 0.000 claims description 8
230000015572 biosynthetic process Effects 0.000 claims description 8
150000002016 disaccharides Chemical class 0.000 claims description 8
238000001471 micro-filtration Methods 0.000 claims description 8
230000001225 therapeutic effect Effects 0.000 claims description 7
239000007853 buffer solution Substances 0.000 claims description 6
230000001965 increasing effect Effects 0.000 claims description 6
229910052751 metal Inorganic materials 0.000 claims description 6
239000002184 metal Substances 0.000 claims description 6
238000002156 mixing Methods 0.000 claims description 5
230000000717 retained effect Effects 0.000 claims description 5
238000002844 melting Methods 0.000 claims description 4
230000008018 melting Effects 0.000 claims description 4
108700025694 p53 Genes Proteins 0.000 claims description 4
238000012545 processing Methods 0.000 claims description 4
238000000108 ultra-filtration Methods 0.000 claims description 4
239000012501 chromatography medium Substances 0.000 claims description 3
238000003825 pressing Methods 0.000 claims description 3
238000007711 solidification Methods 0.000 claims description 3
230000008023 solidification Effects 0.000 claims description 3
125000000185 sucrose group Chemical group 0.000 claims description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
229960004793 sucrose Drugs 0.000 description 17
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 16
238000001943 fluorescence-activated cell sorting Methods 0.000 description 16
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 14
229920000053 polysorbate 80 Polymers 0.000 description 14
239000003599 detergent Substances 0.000 description 12
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 12
229940068968 polysorbate 80 Drugs 0.000 description 12
239000000047 product Substances 0.000 description 12
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 11
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 10
239000000872 buffer Substances 0.000 description 10
239000003381 stabilizer Substances 0.000 description 10
238000012360 testing method Methods 0.000 description 9
238000003556 assay Methods 0.000 description 8
239000013603 viral vector Substances 0.000 description 8
-1 polyoxyethylene Polymers 0.000 description 7
238000000746 purification Methods 0.000 description 7
238000005755 formation reaction Methods 0.000 description 6
238000002523 gelfiltration Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000007983 Tris buffer Substances 0.000 description 5
229960002337 magnesium chloride Drugs 0.000 description 5
229910001629 magnesium chloride Inorganic materials 0.000 description 5
229940050906 magnesium chloride hexahydrate Drugs 0.000 description 5
DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
238000012546 transfer Methods 0.000 description 5
238000000149 argon plasma sintering Methods 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
239000012535 impurity Substances 0.000 description 4
239000012528 membrane Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
235000011008 sodium phosphates Nutrition 0.000 description 4
239000000725 suspension Substances 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
229960005486 vaccine Drugs 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 3
206010035148 Plague Diseases 0.000 description 3
229920001213 Polysorbate 20 Polymers 0.000 description 3
229920001214 Polysorbate 60 Polymers 0.000 description 3
241000607479 Yersinia pestis Species 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000008014 freezing Effects 0.000 description 3
238000007710 freezing Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
159000000003 magnesium salts Chemical class 0.000 description 3
239000000463 material Substances 0.000 description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
230000001256 tonic effect Effects 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
241000701372 Iridovirus Species 0.000 description 2
229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
239000008186 active pharmaceutical agent Substances 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229940031567 attenuated vaccine Drugs 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
150000001923 cyclic compounds Chemical group 0.000 description 2
230000000368 destabilizing effect Effects 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229940088679 drug related substance Drugs 0.000 description 2
238000010828 elution Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000001641 gel filtration chromatography Methods 0.000 description 2
229960005150 glycerol Drugs 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
229910001220 stainless steel Inorganic materials 0.000 description 2
239000010935 stainless steel Substances 0.000 description 2
125000000547 substituted alkyl group Chemical group 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
238000010257 thawing Methods 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
ZWEVPYNPHSPIFU-UHFFFAOYSA-N 2,3,4,5,6-pentahydroxy-n-[3-[3-(2,3,4,5,6-pentahydroxyhexanoylamino)propyl-[4-(3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl)pentanoyl]amino]propyl]hexanamide Chemical compound OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)N(CCCNC(=O)C(O)C(O)C(O)C(O)CO)CCCNC(=O)C(O)C(O)C(O)C(O)CO)C)C1(C)C(O)C2 ZWEVPYNPHSPIFU-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
241001440741 CHER virus Species 0.000 description 1
235000013175 Crataegus laevigata Nutrition 0.000 description 1
102100036227 Cysteine and histidine-rich protein 1 Human genes 0.000 description 1
101000947448 Homo sapiens Cysteine and histidine-rich protein 1 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001219 Polysorbate 40 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108700025701 Retinoblastoma Genes Proteins 0.000 description 1
241000702670 Rotavirus Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000002730 additional effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000002942 anti-growth Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
108010079785 calpain inhibitors Proteins 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000012560 cell impurity Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
159000000006 cesium salts Chemical class 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
229940061607 dibasic sodium phosphate Drugs 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
239000006167 equilibration buffer Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
239000002607 heparin antagonist Substances 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229940091250 magnesium supplement Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940045641 monobasic sodium phosphate Drugs 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
238000012856 packing Methods 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001993 poloxamer 188 Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068977 polysorbate 20 Drugs 0.000 description 1
229940101027 polysorbate 40 Drugs 0.000 description 1
229940113124 polysorbate 60 Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1184-2000A 1998-02-17 1999-02-12 Prostriedok obsahujúci vírus, spôsob jeho koncentrácie a purifikácie SK11842000A3 (sk)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US2446298A	1998-02-17	1998-02-17
US7964398A	1998-05-15	1998-05-15
PCT/US1999/001873 WO1999041416A2 (en)	1998-02-17	1999-02-12	Compositions comprising viruses and methods for concentrating virus preparations

Publications (1)

Publication Number	Publication Date
SK11842000A3 true SK11842000A3 (sk)	2001-05-10

Family

ID=26698472

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1184-2000A SK11842000A3 (sk)	1998-02-17	1999-02-12	Prostriedok obsahujúci vírus, spôsob jeho koncentrácie a purifikácie

Country Status (24)

Country	Link
EP (4)	EP1526173B1 (es)
JP (3)	JP4358434B2 (es)
KR (5)	KR100862169B1 (es)
CN (2)	CN101164623B (es)
AR (3)	AR020054A1 (es)
AT (3)	ATE341614T1 (es)
AU (1)	AU757976B2 (es)
BR (1)	BR9908015A (es)
CA (2)	CA2320419C (es)
CO (1)	CO4820440A1 (es)
DE (3)	DE69942708D1 (es)
DK (1)	DK1054955T3 (es)
ES (2)	ES2290613T3 (es)
HU (1)	HU226015B1 (es)
ID (1)	ID28298A (es)
IL (2)	IL137510A0 (es)
MY (1)	MY141641A (es)
NO (1)	NO20004104L (es)
PE (1)	PE20000265A1 (es)
PL (1)	PL197747B1 (es)
PT (1)	PT1054955E (es)
SK (1)	SK11842000A3 (es)
TW (1)	TWI232107B (es)
WO (1)	WO1999041416A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7732129B1 (en)	1998-12-01	2010-06-08	Crucell Holland B.V.	Method for the production and purification of adenoviral vectors
WO1998022588A2 (en)	1996-11-20	1998-05-28	Introgen Therapeutics, Inc.	An improved method for the production and purification of adenoviral vectors
ATE421337T1 (de) *	1998-11-16	2009-02-15	Introgen Therapeutics Inc	Adenovirus-formulierungen zur gentherapie
US6689600B1 (en)	1998-11-16	2004-02-10	Introgen Therapeutics, Inc.	Formulation of adenovirus for gene therapy
US7456009B2 (en)	2000-03-07	2008-11-25	Merck & Co., Inc.	Adenovirus formulations
EP2420247A1 (en)	2000-03-07	2012-02-22	Merck Sharp & Dohme Corp.	Adenovirus formulations
US20020064860A1 (en)	2000-11-29	2002-05-30	Schering Corporation	Method for purifying adenoviruses
AU2002218535A1 (en) *	2000-12-12	2002-06-24	Japan Tobacco Inc.	Pharmaceutical composition containing an active with a hemolytic action and a surfactant
CA2469623C (en)	2001-12-12	2012-05-29	F H Faulding & Co Limited	Composition for the preservation of viruses
US20030153065A1 (en) *	2002-01-14	2003-08-14	Genvec, Inc.	Composition and method for maintaining non-enveloped viral vectors
BR0306925A (pt) *	2002-01-18	2004-11-09	Schering Ag	Formulações estabilizadas de adenovìrus
US20070207461A1 (en)	2004-02-23	2007-09-06	Crucell Holland B.V.	Virus Purification Methods
CN101080488A (zh)	2004-11-03	2007-11-28	因特罗根治疗公司	生产和纯化腺病毒载体的新方法
CA2590943C (en)	2004-12-13	2013-10-22	Canji, Inc.	Cell lines for production of replication-defective adenovirus
CA2602944C (en)	2005-04-11	2015-08-11	Crucell Holland B.V.	Virus purification using ultrafiltration
CN1961961B (zh) *	2005-11-11	2010-05-26	深圳市源兴生物医药科技有限公司	一种药物制剂及其制备方法
EP1974044B1 (en)	2005-12-12	2011-01-26	CANJI, Inc.	Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
BRPI0710820A2 (pt) *	2006-04-20	2011-08-23	Wyeth Corp	processo para a purificação do vìrus da estomatite vesicular (vsv) do fluido de cultura celular de uma cultura de células de mamìferos infectada com vsv; vsv purificado de acordo com o processo; composição farmacêutica; e composição imunogênica
WO2010060719A1 (en)	2008-11-03	2010-06-03	Crucell Holland B.V.	Method for the production of adenoviral vectors
CN107083400A (zh)	2009-05-02	2017-08-22	建新公司	神经退行性疾病的基因治疗
PL2536829T3 (pl)	2010-02-15	2016-09-30		Sposób wytwarzania wektorów adenowirusowych Ad26
AP3390A (en)	2010-09-20	2015-08-31	Crucell Holland Bv	Therapeutic vaccination against active tuberculosis
US9168292B2 (en)	2010-09-27	2015-10-27	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
EA201390812A1 (ru)	2010-12-02	2013-11-29	Онколитикс Байотек Инк.	Лиофилизированные вирусные составы
MX350932B (es)	2010-12-02	2017-09-26	Oncolytics Biotech Inc	Formulaciones virales liquidas.
US20120273424A1 (en) *	2011-04-29	2012-11-01	Oncolytics Biotech Inc.	Methods of purifying viruses using gel permeation chromatography
US8932607B2 (en)	2012-03-12	2015-01-13	Crucell Holland B.V.	Batches of recombinant adenovirus with altered terminal ends
PL2825640T3 (pl)	2012-03-12	2016-10-31		Partie rekombinowanych adenowirusów o zmienionych końcach
SG11201405804YA (en)	2012-03-22	2014-10-30	Crucell Holland Bv	Vaccine against rsv
US9125870B2 (en)	2012-03-22	2015-09-08	Crucell Holland B.V.	Vaccine against RSV
TR201902513T4 (tr)	2013-04-25	2019-03-21	Janssen Vaccines & Prevention Bv	Stabilize edilmiş çözünebilir prefüzyon RSV F polipeptitleri.
PE20160045A1 (es)	2013-06-17	2016-02-18	Crucell Holland Bv	Polipeptidos f de prefusion del virus sincicial respiratorio (rsv) solubles y estabilizados
EP3149022A4 (en) *	2014-05-28	2018-01-10	Agency for Science, Technology and Research	Virus reduction method
CA2981841A1 (en)	2015-04-14	2016-10-20	Janssen Vaccines & Prevention B.V.	Recombinant adenovirus expressing two transgenes with a bidirectional promoter
AU2016289492B2 (en)	2015-07-07	2022-08-11	Janssen Vaccines & Prevention B.V.	Vaccine against RSV
BR112017028449A2 (pt)	2015-07-07	2018-09-04	Janssen Vaccines & Prevention Bv	polipeptídeos rsv f pré-fusão solúveis estabilizados
ES2858315T3 (es)	2016-04-05	2021-09-30	Janssen Vaccines & Prevention Bv	Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
EA201892250A1 (ru)	2016-04-05	2019-03-29	Янссен Вэксинс Энд Превеншн Б.В.	Вакцина против rsv
IL264119B2 (en)	2016-05-30	2023-04-01	Janssen Vaccines Prevention B V	f proteins of rsv are stabilized before fusion
CN109312362B (zh)	2016-06-20	2022-06-28	扬森疫苗与预防公司	有效和平衡的双向启动子
US10744196B2 (en)	2016-07-14	2020-08-18	Janssen Vaccines & Prevention B.V.	HPV vaccines
EP3624844A1 (en)	2017-05-17	2020-03-25	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
WO2018210871A1 (en)	2017-05-17	2018-11-22	Janssen Vaccines & Prevention B.V.	Methods and compositions for inducing protective immunity against rsv infection
WO2019021305A1 (en) *	2017-07-24	2019-01-31	Ella Foundation	VACCINE AGAINST FOOT AND MOUTH DISEASE
US11229695B2 (en)	2017-09-15	2022-01-25	Janssen Vaccines & Prevention B.V.	Method for the safe induction of immunity against RSV
EP3880243A1 (en)	2018-11-13	2021-09-22	Janssen Vaccines & Prevention B.V.	Stabilized pre-fusion rsv f proteins
CN114173827B (zh) *	2019-06-28	2025-01-28	武田药品工业株式会社	腺相关病毒纯化方法
TW202204380A (zh)	2020-01-31	2022-02-01	美商詹森藥物公司	用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
WO2021186246A1 (en) *	2020-03-19	2021-09-23	Trizell Ltd.	Temperature-responsive virus storage system
MX2023009738A (es)	2021-02-19	2023-08-30	Janssen Vaccines & Prevention Bv	Antigenos de rsv fb prefusion estabilizados.
WO2023020939A1 (en)	2021-08-17	2023-02-23	Janssen Pharmaceuticals, Inc.	Sars-cov-2 vaccines
CN115989321A (zh) *	2021-08-17	2023-04-18	上海行深生物科技有限公司	病毒制剂、用于配制病毒制剂的溶液及其用途
WO2023111725A1 (en)	2021-12-14	2023-06-22	Janssen Pharmaceuticals, Inc.	Sars-cov-2 vaccines

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE299213C (es) *
US4147772A (en) *	1976-02-03	1979-04-03	Merck & Co., Inc.	Vaccine stabilizer
GB1575155A (en) *	1978-04-11	1980-09-17	Merck & Co Inc	Vaccine stabilizer
BE866330A (fr) *	1978-04-25	1978-10-25	Merck & Co Inc	Procede de fabrication d'un agent de stabilisation de vaccin
US5532220A (en)	1987-08-31	1996-07-02	The Regents Of The University Of California	Genetic mechanisms of tumor suppression
DD299213A7 (de) *	1988-05-04	1992-04-09	Saechsische Landesgewerbefoerderungsgesellschaft M.B.H.,De	Verfahren zur stabilisierung eines lebendvirusimpfstoffes gegen temperatureinwirkung
DD295927A5 (de) *	1988-05-06	1991-11-14	Saechsisches Serumwerk Gmbh Dresden,	Immobilisiertes immunologisch aktives reagens
ATE314482T1 (de)	1993-10-25	2006-01-15	Canji Inc	Rekombinante adenoviren-vektor und verfahren zur verwendung
KR100368686B1 (ko) *	1994-12-29	2003-12-01	주식회사 엘지생명과학	수크로즈를이용한세포와바이러스의분리방법
FR2742756B1 (fr) *	1995-12-22	1998-04-03	Pasteur Merieux Serums Vacc	Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
US5789244A (en) *	1996-01-08	1998-08-04	Canji, Inc.	Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems

1999
- 1999-02-12 IL IL13751099A patent/IL137510A0/xx unknown
- 1999-02-12 AT AT99906690T patent/ATE341614T1/de not_active IP Right Cessation
- 1999-02-12 TW TW088102219A patent/TWI232107B/zh not_active IP Right Cessation
- 1999-02-12 EP EP04030394A patent/EP1526173B1/en not_active Expired - Lifetime
- 1999-02-12 PT PT99906690T patent/PT1054955E/pt unknown
- 1999-02-12 CA CA2320419A patent/CA2320419C/en not_active Expired - Fee Related
- 1999-02-12 ES ES04030395T patent/ES2290613T3/es not_active Expired - Lifetime
- 1999-02-12 KR KR1020007008878A patent/KR100862169B1/ko not_active Expired - Fee Related
- 1999-02-12 DK DK99906690T patent/DK1054955T3/da active
- 1999-02-12 AT AT04030395T patent/ATE371020T1/de not_active IP Right Cessation
- 1999-02-12 AT AT06019642T patent/ATE478945T1/de not_active IP Right Cessation
- 1999-02-12 PL PL342847A patent/PL197747B1/pl not_active IP Right Cessation
- 1999-02-12 CN CN2007101670867A patent/CN101164623B/zh not_active Expired - Fee Related
- 1999-02-12 EP EP99906690A patent/EP1054955B1/en not_active Expired - Lifetime
- 1999-02-12 BR BR9908015-0A patent/BR9908015A/pt not_active Application Discontinuation
- 1999-02-12 WO PCT/US1999/001873 patent/WO1999041416A2/en not_active Ceased
- 1999-02-12 KR KR1020097022935A patent/KR101018992B1/ko not_active Expired - Fee Related
- 1999-02-12 DE DE69942708T patent/DE69942708D1/de not_active Expired - Lifetime
- 1999-02-12 KR KR1020087008929A patent/KR100918187B1/ko not_active Expired - Fee Related
- 1999-02-12 JP JP2000531596A patent/JP4358434B2/ja not_active Expired - Fee Related
- 1999-02-12 ES ES99906690T patent/ES2272053T3/es not_active Expired - Lifetime
- 1999-02-12 AU AU26538/99A patent/AU757976B2/en not_active Ceased
- 1999-02-12 DE DE69933433T patent/DE69933433T2/de not_active Expired - Lifetime
- 1999-02-12 EP EP06019642A patent/EP1741777B1/en not_active Expired - Lifetime
- 1999-02-12 ID IDW20001574A patent/ID28298A/id unknown
- 1999-02-12 EP EP04030395A patent/EP1526174B1/en not_active Expired - Lifetime
- 1999-02-12 CN CNB998050989A patent/CN100374551C/zh not_active Expired - Fee Related
- 1999-02-12 KR KR1020087008928A patent/KR100912362B1/ko not_active Expired - Fee Related
- 1999-02-12 HU HU0100670A patent/HU226015B1/hu not_active IP Right Cessation
- 1999-02-12 DE DE69936948T patent/DE69936948T2/de not_active Expired - Lifetime
- 1999-02-12 KR KR1020097004676A patent/KR100991683B1/ko not_active Expired - Fee Related
- 1999-02-12 CA CA2723040A patent/CA2723040A1/en not_active Abandoned
- 1999-02-12 SK SK1184-2000A patent/SK11842000A3/sk unknown
- 1999-02-15 MY MYPI99000542A patent/MY141641A/en unknown
- 1999-02-16 CO CO99009282A patent/CO4820440A1/es unknown
- 1999-02-16 PE PE1999000137A patent/PE20000265A1/es not_active Application Discontinuation
- 1999-02-23 AR ARP990100656A patent/AR020054A1/es active IP Right Grant
2000
- 2000-07-25 IL IL137510A patent/IL137510A/en not_active IP Right Cessation
- 2000-08-16 NO NO20004104A patent/NO20004104L/no not_active Application Discontinuation
2006
- 2006-02-07 JP JP2006030336A patent/JP2006166925A/ja not_active Withdrawn
2007
- 2007-10-16 AR ARP070104577A patent/AR063315A2/es unknown
- 2007-10-16 AR ARP070104576A patent/AR063314A2/es unknown
2010
- 2010-07-08 JP JP2010156257A patent/JP2010213727A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
KR20090127947A (ko)	2009-12-14
ID28298A (id)	2001-05-10
EP1526174A3 (en)	2005-08-31
HU226015B1 (en)	2008-02-28
HUP0100670A2 (hu)	2001-06-28
DE69936948T2 (de)	2008-05-15
EP1741777B1 (en)	2010-08-25
IL137510A0 (en)	2001-07-24
PE20000265A1 (es)	2000-04-25
PL197747B1 (pl)	2008-04-30
KR20090038927A (ko)	2009-04-21
EP1526174B1 (en)	2007-08-22
NO20004104D0 (no)	2000-08-16
CN1297478A (zh)	2001-05-30
KR100862169B1 (ko)	2008-10-09
JP2002503484A (ja)	2002-02-05
KR20080065615A (ko)	2008-07-14
AR063315A2 (es)	2009-01-21
EP1054955A2 (en)	2000-11-29
EP1741777A1 (en)	2007-01-10
ES2290613T3 (es)	2008-02-16
CN101164623B (zh)	2012-11-14
JP2010213727A (ja)	2010-09-30
ATE341614T1 (de)	2006-10-15
HK1028416A1 (en)	2001-02-16
JP2006166925A (ja)	2006-06-29
EP1526174A2 (en)	2005-04-27
AU757976B2 (en)	2003-03-13
NO20004104L (no)	2000-10-17
EP1526173A3 (en)	2005-08-10
HUP0100670A3 (en)	2003-10-28
CN101164623A (zh)	2008-04-23
AR063314A2 (es)	2009-01-21
EP1526173B1 (en)	2012-11-21
KR100918187B1 (ko)	2009-09-22
PL342847A1 (en)	2001-07-16
KR20010072547A (ko)	2001-07-31
DE69933433D1 (de)	2006-11-16
HK1073481A1 (en)	2005-10-07
CA2320419A1 (en)	1999-08-19
EP1054955B1 (en)	2006-10-04
TWI232107B (en)	2005-05-11
KR20080065614A (ko)	2008-07-14
CA2723040A1 (en)	1999-08-19
MY141641A (en)	2010-05-31
DE69942708D1 (de)	2010-10-07
HK1097413A1 (en)	2007-06-22
DE69933433T2 (de)	2007-08-23
DE69936948D1 (de)	2007-10-04
ATE478945T1 (de)	2010-09-15
ES2272053T3 (es)	2007-04-16
ATE371020T1 (de)	2007-09-15
CN100374551C (zh)	2008-03-12
BR9908015A (pt)	2001-04-24
WO1999041416A3 (en)	1999-11-18
KR101018992B1 (ko)	2011-03-07
PT1054955E (pt)	2007-01-31
WO1999041416A2 (en)	1999-08-19
KR100912362B1 (ko)	2009-08-19
CA2320419C (en)	2011-02-08
JP4358434B2 (ja)	2009-11-04
IL137510A (en)	2012-10-31
CO4820440A1 (es)	1999-07-28
EP1526173A2 (en)	2005-04-27
KR100991683B1 (ko)	2010-11-04
DK1054955T3 (da)	2007-01-15
AR020054A1 (es)	2002-04-10
AU2653899A (en)	1999-08-30

Publication	Publication Date	Title
SK11842000A3 (sk)	2001-05-10	Prostriedok obsahujúci vírus, spôsob jeho koncentrácie a purifikácie
US20080293123A1 (en)	2008-11-27	Compositions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en)	2008-10-23	Compositions comprising viruses and methods for concentrating virus preparations
CZ20002864A3 (cs)	2000-11-15	Prostředek obsahující virus, způsoby jeho koncentrace a purifikace
HK1073480A (en)	2005-10-07	Compositions comprising viruses and methods for concentrating virus preparations
HK1028416B (en)	2007-03-02	Compositions comprising viruses and methods for concentrating virus preparations
HK1073481B (en)	2008-01-18	Compositions comprising viruses and methods for concentrating virus preparations
NZ505952A (en)	2002-02-01	Compositions comprising viruses and methods for concentrating virus preparations
HK1097413B (en)	2010-11-12	Compositions comprising viruses and methods for concentrating virus preparations
MXPA00008008A (es)	2001-07-09	Composiciones que contienen virus y metodos para concentrar preparados de virus